Current position:News > News > Insights
CD38: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
吉满生物
2024-09-23

June 3, 2024. Sanofi issued a press release stating that its CD38 monoclonal antibody Sarclisa has been approved in the United States as the first anti-CD38 therapy.

Sarclisa is the first anti-CD38 drug to significantly improve progression-free survival in combination with VRd for the treatment of newly diagnosed transplant-eligible multiple myeloma.

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival (PFS), compared to standard-of-care in newly diagnosed adult patients not eligible for autologous stem cell transplant (ASCT).

Third indication for Sarclisa, evaluated under FDA Priority Review, underscores Sanofi’s commitment to helping close a critical care gap in multiple myeloma (MM).

Genomeditech launches stable high-expression cell lines and antibody products to help CD38 drug development! Click here to learn more about our CD38 catalog

Latest news
Insights
2025-12-17
Could GDF15 Become the Next Super Target After PD-1 and GLP-1?
A recent Nature Aging study reveals that senescent tumor-adjacent epithelial cells secrete GDF15, driving colorectal cancer progression via a metabolic–epigenetic feedback loop. This expands GDF15’s role beyond tumor cells to its influence on the surrounding microenvironment.

Emerging as a hub connecting tumor growth, immune evasion, and systemic metabolism, GDF15 is a promising target across oncology, cancer cachexia, obesity, and metabolic diseases. Monoclonal antibodies like Ponsegromab and Visugromab are showing encouraging results in early clinical trials.
Insights
2025-12-12
ADCC, ADCP, and CDC: Antibody Structure and Class Considerations
Antibodies have evolved into versatile therapeutic platforms, capable of not only targeting disease cells but also activating the immune system through ADCC, ADCP, and CDC. Advances in Fc engineering—such as glycoengineering, targeted mutations, and FcRn optimization—are now enhancing antibody potency, selectivity, and half-life, unlocking new opportunities in oncology, autoimmune disorders, and infectious diseases.
Insights
2025-12-04
BCMA Drives Accelerated Expansion into the Autoimmune Therapeutics Field
BCMA, a well-established target in blood cancers, is now expanding its impact into autoimmune diseases. Leveraging its highly specific expression and favorable safety profile, BCMA is at the forefront of innovative therapies, including CAR-T cells, bispecific and trispecific antibodies, and antibody-drug conjugates.

Recent collaborations and rapid clinical advancements highlight BCMA as a key focus for next-generation immune-targeted treatments. Learn how this promising target is reshaping the future of immunotherapy and opening new possibilities for patients worldwide.
Current position:News > News > Insights
classify
CD38: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
吉满生物
2024-09-23

June 3, 2024. Sanofi issued a press release stating that its CD38 monoclonal antibody Sarclisa has been approved in the United States as the first anti-CD38 therapy.

Sarclisa is the first anti-CD38 drug to significantly improve progression-free survival in combination with VRd for the treatment of newly diagnosed transplant-eligible multiple myeloma.

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival (PFS), compared to standard-of-care in newly diagnosed adult patients not eligible for autologous stem cell transplant (ASCT).

Third indication for Sarclisa, evaluated under FDA Priority Review, underscores Sanofi’s commitment to helping close a critical care gap in multiple myeloma (MM).

Genomeditech launches stable high-expression cell lines and antibody products to help CD38 drug development! Click here to learn more about our CD38 catalog

Message consultation
reset
submit
Message
Message consultation
reset
submit